Healthy Clinical Trial
— PolyGlucHealOfficial title:
Effects of Enriched Fruit Juice on Blood Glucose Levels After a Meal in Healthy Subjects
Results from a large number of studies in humans have shown that diets rich in foods that
give lower glucose response bring lower risk of type 2 diabetes. Polyphenols, naturally found
in fruits, vegetables and grains, have shown the potential to attenuate post-prandial blood
glucose spikes following a carbohydrate-rich meal, through partial inhibition of the main
enzymes of carbohydrate digestion and reduction in glucose and fructose transport from the
gut after digestion and by enhancing the insulin action after glucose reaches the
bloodstream.
This study is designed to determine whether polyphenols, as normally and naturally present in
food extracts and beverages, added to a carbohydrate-rich meal, can lower blood glucose
levels after its consumption, and hence lower its glycaemic index, and if this effect is
mediated through effects on insulin and other hormones. The study is designed as an acute,
double-blind, randomised, placebo-controlled crossover trial in 24 healthy subjects with
normal glycaemic response to white bread. Participants will be asked to consume either white
bread with pomegranate juice enriched with extracts from grape seeds and apple peels or white
bread with placebo drink. The effects on plasma glucose levels, levels of hormones and other
biomarkers involved in postprandial response will be determined over 3 hours after the
consumption.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | September 1, 2018 |
Est. primary completion date | August 20, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Fasting glucose = 5.6 mM; - Body mass index (BMI) = 30; - Max glucose after the consumption of app. 109g of white bread less than about 8-9 mM (which is typical for the subjects we have measured previously); Exclusion Criteria: - Smoking; - Participating in another trial that requires blood collection; - Diagnosed with any chronic illness (including diabetes, hypertension etc.); - On long term prescribed medication (except contraceptives); - Pregnant or lactating; - On a special diet or dietary regimen (for weight management or if regularly consuming fruit extract supplements); - Allergy to fruits vegetables or pollen. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | School of Food Science and Nutrition, University of Leeds | Leeds | West Yorkshire |
Lead Sponsor | Collaborator |
---|---|
University of Leeds |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in organic acids profile between baseline and endpoint within the intervention group vs. placebo control. | Levels of selected organic acids measured in plasma at the baseline and at each time point (at 15, 30, 45, 60, 90,120, 150 and 180 min) after the consumption of test and control meals. | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. | |
Other | Changes in fatty acids profile between baseline and endpoint within the intervention group vs. placebo control. | Levels of selected free-fatty acids measured in serum at the baseline and at each time point (at 15, 30, 45, 60, 90,120, 150 and 180 min) after the consumption of test and control meals. | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. | |
Other | Changes in triglycerides levels between baseline and endpoint within the intervention group vs. placebo control. | Levels of triglycerides measured in serum at the baseline and at each time point (at 15, 30, 45, 60, 90,120, 150 and 180 min) after the consumption of test and control meals. | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. | |
Primary | Changes in maximal incremental plasma glucose level (iCmax) between baseline and endpoint within the intervention group vs. placebo control. | The incremental glucose levels will be determined for each time point (at 15, 30, 45, 60, 90, 120, 150 and 180 min) as the change in plasma glucose levels after the consumption of enriched pomegranate juice or placebo drink concomitantly with white bread, compared to the glucose levels before the consumption of test meals (baseline value, t=0min). | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. | |
Secondary | Changes in area under the curve of incremental plasma glucose levels (iAUC) in the intervention group vs. placebo control. | The glucose iAUC will be determined from all incremental plasma glucose levels at the defined time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 min) after the consumption of test and control meals based on trapezoid rule. | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. | |
Secondary | Changes in plasma insulin levels between baseline and endpoint within the intervention group vs. placebo control. | Insulin levels measured at the baseline and at each time point (at 15, 30, 45, 60, 90,120, 150 and 180 min) after the consumption of test and control meals. | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. | |
Secondary | Changes in plasma gastric inhibitory peptide (GIP) levels between baseline and endpoint within the intervention group vs. placebo control. | GIP levels measured in plasma at the baseline and at each time point (at 15, 30, 45, 60, 90,120, 150 and 180 min) after the consumption of test and control meals. | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. | |
Secondary | Changes in glucagon-like peptide-1 (GIP-1) levels between baseline and endpoint within the intervention group vs. placebo control. | GLP-1 levels measured in plasma at the baseline and at each time point (at 15, 30, 45, 60, 90,120, 150 and 180 min) after the consumption of test and control meals. | Baseline, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 150 min, 180 min. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |